Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Inovio Strikes First Partnership, In Emerging Markets, For Lead Product

Executive Summary

Inovio's new licensing deal for its most advanced pipeline asset gives the US firm not only its first partner for the cervical dysplasia vaccine but also a presence in a major emerging market.


Related Content

Deal Watch: Seattle Genetics Adds To Antibody-Drug Conjugate Portfolio
China Approves First HPV Vaccine But Can GSK Secure Its Lead?
Genexine Raises New Funds To Progress Promising HPV, Other Projects


Related Companies